Active Ingredient History
Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Atherosclerosis (approved 2021)
Acute Coronary Syndrome (Phase 3)
Atherosclerosis (Phase 3)
Coronary Artery Disease (Phase 3)
Diabetes Mellitus (Phase 2)
Diabetes Mellitus, Type 2 (Phase 2)
Heart Disease Risk Factors (Phase 3)
Heart Diseases (Phase 3)
Homozygous Familial Hypercholesterolemia (Phase 3)
Hypercholesterolemia (Phase 4)
Hyperlipidemias (Phase 1)
Hyperlipoproteinemia Type II (Phase 2)
Kidney Failure, Chronic (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
